Senores Pharmaceuticals Limited — Investor Meet, 13-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Senores Pharma crushed Q2 & H1 FY26! Consolidated income rose 61% (Q2) and 66% (H1) YoY. PAT jumped 131% (Q2) and 114% (H1). Regulated market revenue soared 87% YoY with 44% EBITDA margins. Emerging markets showed sequential growth, targeting 15-20% EBITDA next year. Branded generics revenue exploded 10x YoY. Management reiterated FY26 guidance of 50% top-line and 100% PAT growth. They're expanding US capacity, launching new products, and integrating an API facility. Overall, confident outlook with sustainable 25-30% growth and 28-30% EBITDA margins long-term.